Search ClinicalTrials.gov by condition, drug/device or sponsor: status, phase, e...
https://bess-x402.onrender.com/v1/health/clinical-trialsOverview
Search ClinicalTrials.gov by condition, drug/device or sponsor: status, phase, enrollment, start and completion dates, sponsor, interventions and countries. Use for pharma, biotech and patient research.
Protocol
x402
Price
$0.0030
Payment Asset
USD Coin
Payment Network
eip155:8453
Category
tools/search
Provider
Clinical Trials Search
Source
bazaar
Indexed
2026-10-26 02:40:27
Health
Status
healthy
Latency (p50)
255ms
Uptime (30d)
100.0%
Reliability Score
92/100
Last Checked
2026-10-31 07:19:38
Last Healthy
2026-10-31 07:19:38
Consecutive Failures
0
x402 Payment Validation
Payment Requirements
Valid
Asset Verified
Known USDC
Facilitator
—
Input Schema
{
"method": "GET",
"queryParams": {
"condition": "obesity",
"limit": 3,
"status": "recruiting"
},
"type": "http"
}
Output Schema
{
"example": {
"count": 3,
"source": "ClinicalTrials.gov (US National Library of Medicine)",
"studies": [
{
"conditions": [
"Obese",
"Overweight"
],
"countries": [
"Australia"
],
"enrollment": 40,
"interventions": [
"SA030 Injection",
"Matching Placebo"
],
"last_update": "2026-10-23",
"nct_id": "NCT07479862",
"phases": [
"PHASE1"
],
"primary_completion": "2028-04-24",
"sponsor": "Suzhou Siran Biotechnology Co.,Ltd.",
"sponsor_class": "INDUSTRY",
"start": "2026-04-16",
"status": "RECRUITING",
"summary": "This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight or obese.\n\nOver the last few decades, more and more people around the w...",
"title": "A Study of SA030 Injection in Overweight or Obese Participants",
"type": "INTERVENTIONAL",
"url": "https://clinicaltrials.gov/study/NCT07479862"
},
{
"conditions": [
"Chronic Weight Management"
],
"countries": [
"United States"
],
"enrollment": 144,
"interventions": [
"ASC36 Injection A, for subcutaneous use",
"ASC36 Placebo Injection A, for subcutaneous use"
],
"last_update": "2026-10-23",
"nct_id": "NCT07893093",
"phases": [
"PHASE1"
],
"primary_completion": "2027-06",
"sponsor": "Ascletis Pharma (China) Co., Limited",
"sponsor_class": "INDUSTRY",
"start": "2026-09-28",
"status": "RECRUITING",
"summary": "This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of ASC36 injection",
"title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight",
"type": "INTERVENTIONAL",
"url": "https://clinicaltrials.gov/study/NCT07893093"
}
],
"total": 1477
},
"type": "json"
}